CoChat

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance

Open access
Li, Qing-Hai, Wang, Ying-Zhao, Tu, Jian, Liu, Chu-Wei, Yuan, Yu-Jie, Lin, Run, He, Wei-Ling, Cai, Shi-Rong, He, Yu-Long, Ye, Jin-Ning · 2020 · Gastroenterology Report

The DOI matches its Crossref record; 165 of the 166 references it cites were found in a registry or an index.

Abstract

Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer (mCRC). These agents have good curative efficacy, but drug resistance also exists at the same time. The effects of KRAS, NRAS, and BRAF mutations and HER2 amplification on the treatment of refractory mCRC have been elucidated and the corresponding countermeasures have been put forward. However, the changes in EGFR and its ligands, the mutations or amplifications of PIK3CA, PTEN, TP53, MET, HER3, IRS2, FGFR1, and MAP2K1, the overexpression of insulin growth factor-1, the low expression of Bcl-2-interacting mediator of cell death, mismatch repair-deficient, and epigenetic instability may also lead to drug resistance in mCRC. Although the emergence of drug resistance has genetic or epigenetic heterogeneity, most of these molecular changes relating to it are focused on the key signaling pathways, such as the RAS/RAF/mitogen-activated protein kinase or phosphatidylinositol 3-kinase/Akt/mammalian target of the rapamycin pathway. Accordingly, numerous efforts to target these signaling pathways and develop the novel therapeutic regimens have been carried out. Herein, we have reviewed the underlying mechanisms of the resistance to anti-EGFR therapy and the possible implications in clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/gastro/goaa026

Cites

165 of 165 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. EGFR signaling and potential regimens in cetuximab- or panitumumab-resistant mCRC. In addition to NRAS/KRAS/BRAF mutations, low expression of EGFR/AREG/EREG, the mutations of extracellular domains of EGFR, PIK3CA, PTEN, TP53, and MEK1 are related to cetuximab or panitumumab resistance. The agents targeting BRAF and MEK1/2 have been approved for the subsequent therapy of advanced or metastatic CRC; some other targeted drugs such as PI3K, Mtor, and RAS inhibitors also deserve our attention, especially the KRAS G12C inhibitors AMG-510 and MRTX849. EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HB-EGF, heparin-binding EGF; TGF-α, transforming growth factor α; AREG, amphiregulin; EREG, epiregulin; ED, extracellular domains; TKD, tyrosine kinase domains; GRB2, growth factor receptor bound-2; SOS, son of sevenless; MEK1/2, mitogen-activated protein kinase kinase; ERK1/2, extracellular-signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; mTOR, mammalian target of rapamycin; p, phosphorylation; * have been approved for markets.
Figure 1. EGFR signaling and potential regimens in cetuximab- or panitumumab-resistant mCRC. In addition to NRAS/KRAS/BRAF mutations, low expression of EGFR/AREG/EREG, the mutations of extracellular domains of EGFR, PIK3CA, PTEN, TP53, and MEK1 are related to cetuximab or panitumumab resistance. The agents targeting BRAF and MEK1/2 have been approved for the subsequent therapy of advanced or metastatic CRC; some other targeted drugs such as PI3K, Mtor, and RAS inhibitors also deserve our attention, especially the KRAS G12C inhibitors AMG-510 and MRTX849. EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HB-EGF, heparin-binding EGF; TGF-α, transforming growth factor α; AREG, amphiregulin; EREG, epiregulin; ED, extracellular domains; TKD, tyrosine kinase domains; GRB2, growth factor receptor bound-2; SOS, son of sevenless; MEK1/2, mitogen-activated protein kinase kinase; ERK1/2, extracellular-signal-regulated kinase; PI3K, phosphatidylinositol 3-kinase; mTOR, mammalian target of rapamycin; p, phosphorylation; * have been approved for markets.CC BY · PubMed Central
Figure 2. The clinical process of changing tumor inhibition to drug resistance and tumor progression. This process is extremely complex and highly heterogeneous because there are both innate and acquired factors that contribute to the occurrence of drug resistance and the strategy of combined targeted chemotherapy deserves our attention.
Figure 2. The clinical process of changing tumor inhibition to drug resistance and tumor progression. This process is extremely complex and highly heterogeneous because there are both innate and acquired factors that contribute to the occurrence of drug resistance and the strategy of combined targeted chemotherapy deserves our attention.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 165 references

Cited by

See all 125

Metadata

Authors
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N.
Affiliations
  • Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China
  • The First Affiliated Hospital, Sun Yat-sen University (CN)
Venue
Gastroenterology Report
Published
2020-06-01
Volume
8
Issue
3
Pages
179-191
ISSN
2052-0034 (ISSN-L)
OpenAlex
W3037750477
Cited by
119
References
166
Citations by year
2026: 12 · 2025: 25 · 2024: 23 · 2023: 17 · 2022: 23 · 2021: 17 · 2020: 1
FWCI
1.56
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology report (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81871994, 81701834)
  • Guangdong Natural Science Foundation (2019B151502063)
  • Guangdong Science and Technology Planning Program (20190202018)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
anti-EGFR therapy, metastatic colorectal cancer, drug resistance, cetuximab, panitumumab, EGFR mutation, KRAS, NRAS, BRAF, HER2 amplification, PIK3CA, PTEN, TP53, MET, HER3, insulin receptor substrate 2, FGFR1, MEK1, insulin-like growth factor I, mismatch repair deficiency, epigenetic instability, Ras/Raf/MEK signaling, PI3K/AKT/mTOR pathway, combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. https://app.cochat.ai/papers/10.1093/gastro/goaa026
The paper
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020). Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterology Report. https://doi.org/10.1093/gastro/goaa026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.